EGFR and non-small cell lung carcinoma: Our study compared the efficacy of four immunotherapy-based therapies with chemotherapy alone or chemotherapy plus anti-angiogenesis to find the optimal treatment regimen for NSCLC patients after EGFR-TKIs failure.